eli lilly glp-1 agonist Lilly's Next-Generation GLP-1R Naperiglipron—Structure Revealed Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces
Description
GLP-1RAs and related incretin-based therapies contribute to sustained weight loss in obese individuals, which is accompanied by improvements in related comorbidities
Starting with a lower dose and gradually increasing (dose titration) helps minimise these symptoms
Through its action on neurons projecting from the nucleus tractus solitarius to the hypothalamus, GLP-1 also promotes satiety
S.Honkanen-ScottM.ShawJ.LovatP
Wegovy is more expensive than Ozempic, even on a mg per mg basis
